SHR-7590 / Jiangsu Hengrui Pharma - LARVOL DELTA

SHR-7590-101: A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel Disease (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting | N=64 ➔ 88

Enrollment change • Enrollment open • First-in-human • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

SHR-7590-101: A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-Severe Ulcerative Colitis (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

First-in-human • New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis